Double-vessel very late stent thrombosis following Resolute Onyx zotarolimus eluting stents implantation in an octogenarian

• 来源期刊: 老年心脏病学杂志（英文版）
• 年，卷（期）: 2018,（10）
• 页码范围: 639-643
• 页数: 5页
• 语种: 英文
• DOI: 10.11909/j.issn.1671-5411.2018.10.001

摘要

Compared with bare-metal stents (BMS),drug-eluting stents (DES) have shown better clinical outcomes for patients undergoing percutaneous coronary intervention (PCI) by inhibition of neo-intimal hyperplasia,[1] However,earlygeneration DES produced late thrombotic events,more than l-year,by delaying arterial healing of stented vessels.[2-5] New-generation DES have been developed with thinner stent struts,more biocompatible polymer coatings for drug release,and a variety of antiproliferative agents with similar or superior anti-restenotic efficacy.[6] This development has led to a significant improvement in the efficacy and safety of new-generation DES,and consistently lower rates of very late stent thrombosis (VLST).[7,8] In fact,use of new-generation DES is the standard treatment in contemporary PCI practice.